Coronary Artery DiseasePhase 2Q-CABGNCT04907253

Quercetin in Coronary Artery By-pass Surgery

A Phase 2 study testing Quercetin in people with Coronary Artery Disease, run by Montreal Heart Institute at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The purpose of this study is to test the anti-inflammatory and anti-senescence effects of quercetin during coronary artery by-pass graft surgery. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Coronary Artery Disease
What is being tested?: Quercetin
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 100 participants
Where: 1 siteCanada
Study dates: 4 Jun 2021to 16 May 2025
Phase: Phase 2
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

to be able to speak French or English;
to be able to give free and enlighten consent;
be hospitalized and waiting for a cardiac surgery of revascularization;
to have had a myocardial infarction (MI) within the past 30 days or to be in a state of stable angina before the surgery.

Who cannot join

to be in a stable state without MI in the last 30 days;
have a cardiac surgery concomitant to the cardiac surgery of revascularization;
have an infection in the last 30 days;
to have renal insufficiency (GFR less than 30);
to have a liver disease (AST, ALT or bilirubin ˃ 2X normal values);
to have a known cirrhosis;

Show all 13Show fewer

to have a past history of breast cancer or other tumors estrogen-dependent;
to be intolerant to flavonoids, niacine or ascorbic acid;
take quinolone;
need for a quinolone during post-op;
not being able to give a free and enlighten consent;
not being able to speak French of English;
take quercetin as a supplement.

Trial locations and contacts

1 site in 1 country.

Canada1 site

Montreal Heart Institute
Montreal, Quebec, H1T 1C8

Other trials in Canada

About this study

Official title: Étude randomisée contrôlée Par Placebo de Phase II Visant à Mesurer l'Effet Anti-inflammatoire et Anti-sénescence de la quercétine Lors d'Une Chirurgie Cardiaque

The purpose of this study is to test the anti-inflammatory and anti-senescence effects of quercetin during coronary artery by-pass graft surgery.

Read the detailed description

After being informed about the study and the potential risk, all patients giving written informed consent will be randomized in a double-blind manner (participant and investigators) on 1:1 ratio to receive quercetin (500 mg twice daily) or placebo (twice daily) starting 2 days before a coronary artery by-pass graft surgery and for the duration of their hospitalization but up to 10 days (i.e. up to 7 days post-surgery). Blood (5 ml) will be collected the first morning after recruitment (t-1), 24h post-surgery (t1), day 4 post-surgery (t2) and day of hospital discharge for blood analyses. During the surgery, if a discarded segment of mammary artery is available, it will be collected for laboratory work. Health status will be assessed during the follow-up visit 8 to 12 weeks post-surgery.

Conditions: Coronary Artery Disease
Being tested: Quercetin, Placebo
Keywords: Inflammation, Endothelium, Senescence, Vascular reactivity
Medical subject headings: Coronary Artery Disease, Inflammation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

QuercetinDrug
500 mg twice daily
PlaceboDrug
twice daily

Study groups in NCT04907253
Study group	Role	What they receive
Quercetin	Active comparator	Patients receiving 500 mg quercetin twice daily Receives: Drug: Quercetin
Placebo	Placebo comparator	Patients receiving placebo twice daily Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Quercetin-associated Change in Surgery-associated Inflammation
Circulating blood levels of hs-CRP (mg/L) will be measured as well as a panel of circulating inflammatory markers in a subgroup of patients at day 5 post-surgery
Measured: Baseline, 1 day and 4 days post-surgery
Quercetin-associated Change in Surgery-associated Marker of Senescence
Circulating blood levels of ANGPTL2 (ng/L) will be measured in addition to additional circulating markers of inflammation in a sub-group of patients at day 4 post-surgery
Measured: Baseline, 1 day and 4 days post-surgery

Secondary outcomes (1)

Acetylcholine Concentration (nM) Required for EC50 in Endothelium-dependent Relaxation
A discarded segment of the mammary artery will be collected at the end of the cardiac surgery when available.
One portion of the segment will be used to study the endothelium-dependent relaxation ex vivo. Segments will be mounted on a wire myograph. After an equilibration period, it will be pre-contracted with U46619 (0.1 µM): when the pre-contraction is stable, a cumulative dose-response curve to acetylcholine is built to induce an endothelium-dependent relaxation. Relaxation will be determined by the vascular sensitivity to acetylcholine (nM).
IMPORTANT: at completion of the study, the analysis revealed that during the surgery, only 34 arterial segments from patients in the quercetin group and 44 segments from patients in the placebo group were made available by the surgeon. Therefore, only these 78 arterial segments were analyzed for this outcome measure of the ITT population (n=97).
Measured: During surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

4 Jun 202116 May 2025

First posted28 May 2021
Study start4 Jun 2021
Primary completion1 Dec 2023
Study completion16 May 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (3)Papers the sponsor has linked to this study.
Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Model description: Randomized, double-blind, placebo-controlled
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 100 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT04907253
Sponsor's protocol ID: 2021-2761
Acronym: Q-CABG
Status last verified: Sep 2025
First submitted: 12 May 2021
Last updated: 15 Apr 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Publications

Noly PE, Labbe P, Thorin-Trescases N, Fortier A, Nguyen A, Thorin E, Carrier M. Reduction of plasma angiopoietin-like 2 after cardiac surgery is related to tissue inflammation and senescence status of patients. J Thorac Cardiovasc Surg. 2019 Sep;158(3):792-802.e5. doi: 10.1016/j.jtcvs.2018.12.047. Epub 2019 Jan 8.
PubMed 30745045
Mury P, Dagher O, Fortier A, Diaz A, Lamarche Y, Noly PE, Ibrahim M, Page P, Demers P, Bouchard D, Bernier PL, Poirier N, Moss E, Durrleman N, Jeanmart H, Pellerin M, Lettre G, Thorin-Trescases N, Carrier M, Thorin E. Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients. Aging Cell. 2025 Aug;24(8):e70108. doi: 10.1111/acel.70108. Epub 2025 May 15.
PubMed 40375481
Dagher O, Mury P, Noly PE, Fortier A, Lettre G, Thorin E, Carrier M. Design of a Randomized Placebo-Controlled Trial to Evaluate the Anti-inflammatory and Senolytic Effects of Quercetin in Patients Undergoing Coronary Artery Bypass Graft Surgery. Front Cardiovasc Med. 2021 Oct 20;8:741542. doi: 10.3389/fcvm.2021.741542. eCollection 2021.
PubMed 34746258

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingObservational study
Assessment of Transnational Performance of the Universal Cardiac Surgical Risk Score Across International Sites
Heart Valve Diseases, Cardiac Surgical Procedures
Not yet recruiting
Sirolimus-Coated Versus Paclitaxel-Coated Balloon for Recurrent Coronary In-Stent Restenosis After Prior Paclitaxel-Coated Balloon Treatment (SPRIT)
Coronary In-stent Restenosis, Coronary Artery Disease
RecruitingObservational study
Norepinephrine in the Management of General Anesthesia-Induced Arterial Hypotension in Chronic Heart Failure Patients
Hypotension
Active, not recruitingObservational study
The CoPenHagen PREeClampsia and cardIOvascUlar diSease Study
Pre-Eclampsia, Atherosclerosis
RecruitingObservational study
Cardiovascular Risk Assessment For Kidney Transplantation - Utility of Computed Tomography Coronary Angiography in the Assessment of Patients Awaiting Kidney Transplantation
Cardiovascular Diseases, Kidney Transplant; Complications

All Coronary Artery Disease trials

Study at a glance

From the registry record, last updated by the sponsor on 15 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Étude randomisée contrôlée Par Placebo de Phase II Visant à Mesurer l'Effet Anti-inflammatoire et Anti-sénescence de la quercétine Lors d'Une Chirurgie Cardiaque
ClinicalTrials.gov ID: NCT04907253
Acronym / sponsor ID: Q-CABG / 2021-2761
Conditions: Coronary Artery Disease
Keywords: Inflammation, Endothelium, Senescence, Vascular reactivity
Phase: Phase 2
Study type: Interventional
Recruitment status: Completed
Enrolment: 100 participants (actual)
Lead sponsor: Montreal Heart InstituteUniversity, hospital or other
Study start: 4 Jun 2021 (actual)
Primary completion: 1 Dec 2023 (actual)
Study completion: 16 May 2025 (actual)
First posted: 28 May 2021 (actual)
Results: Posted 15 Apr 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The purpose of this study is to test the anti-inflammatory and anti-senescence effects of quercetin during coronary artery by-pass graft surgery.

Detailed description

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 2
Model description: Randomized, double-blind, placebo-controlled

Arm	Type	Receives
Quercetin	Active comparator	Drug: QuercetinPatients receiving 500 mg quercetin twice daily
Placebo	Placebo comparator	Drug: PlaceboPatients receiving placebo twice daily

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (4 listed)

to be able to speak French or English;
to be able to give free and enlighten consent;
be hospitalized and waiting for a cardiac surgery of revascularization;
to have had a myocardial infarction (MI) within the past 30 days or to be in a state of stable angina before the surgery.

Key exclusion criteria (13 listed)

to be in a stable state without MI in the last 30 days;
have a cardiac surgery concomitant to the cardiac surgery of revascularization;
have an infection in the last 30 days;
to have renal insufficiency (GFR less than 30);
to have a liver disease (AST, ALT or bilirubin ˃ 2X normal values);

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Quercetin500 mg twice daily	Drug	Quercetin
Placebotwice daily	Drug	Placebo

Primary outcome

Quercetin-associated Change in Surgery-associated Inflammation
Time frame: Baseline, 1 day and 4 days post-surgery
Circulating blood levels of hs-CRP (mg/L) will be measured as well as a panel of circulating inflammatory markers in a subgroup of patients at day 5 post-surgery
Quercetin-associated Change in Surgery-associated Marker of Senescence
Time frame: Baseline, 1 day and 4 days post-surgery
Circulating blood levels of ANGPTL2 (ng/L) will be measured in addition to additional circulating markers of inflammation in a sub-group of patients at day 4 post-surgery

1 secondary outcome

Acetylcholine Concentration (nM) Required for EC50 in Endothelium-dependent Relaxation
Time frame: During surgery

Results and safety

Results posted to the registry on 15 Apr 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Placebo	50	50
Quercetin	50	47

Primary outcome: Quercetin-associated Change in Surgery-associated Inflammation

Time frame: Baseline, 1 day and 4 days post-surgery. Mean (Standard Deviation). Unit: mg/L

Measure	Placebo n = 50	Quercetin n = 47
Baseline Women	9 (5)	3 (1)
t1 women	87 (10)	109 (16)
t4 women	85 (10)	19 (17)
Baseline men	7 (2)	8 (3)
t1 men	113 (6)	119 (6)
t4 men	127 (8)	128 (7)

Population analysed: Men and women treated with quercetin or placebo starting 2 days before surgery

Primary outcome: Quercetin-associated Change in Surgery-associated Marker of Senescence

Time frame: Baseline, 1 day and 4 days post-surgery. Mean (Standard Error). Unit: ng/L

Measure	Quercetin n = 47	Placebo n = 50
Baseline women	6.8 (0.5)	5.5 (0.4)
t1 women	6.7 (0.4)	7.4 (1.0)
t4 women	7.5 (0.6)	7.3 (0.4)
baseline men	5.8 (0.3)	6.2 (0.2)
t1 men	7.0 (0.3)	7.0 (0.2)
t4 men	7.2 (0.3)	7.5 (0.3)

Population analysed: Men and women treated with quercetin or placebo starting 2 days before surgery

1 secondary outcome is reported in the full results.

Adverse events

Time frame: 3 months. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Placebo	0 of 50 (0%)	0 of 50 (0%)	0 of 50
Quercetin	0 of 47 (0%)	0 of 47 (0%)	0 of 47

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 15 Apr 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Background: PubMed 30745045Noly PE, Labbe P, Thorin-Trescases N, Fortier A, Nguyen A, Thorin E, Carrier M. Reduction of plasma angiopoietin-like 2 after cardiac surgery is related to tissue inflammation and senescence status of patients. J Thorac Cardiovasc Surg. 2019 Sep;158(3):792-802.e5. doi: 10.1016/j.jtcvs.2018.12.047. Epub 2019 Jan 8.
Results publication: PubMed 40375481Mury P, Dagher O, Fortier A, Diaz A, Lamarche Y, Noly PE, Ibrahim M, Page P, Demers P, Bouchard D, Bernier PL, Poirier N, Moss E, Durrleman N, Jeanmart H, Pellerin M, Lettre G, Thorin-Trescases N, Carrier M, Thorin E. Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients. Aging Cell. 2025 Aug;24(8):e70108. doi: 10.1111/acel.70108. Epub 2025 May 15.
Derived from this study: PubMed 34746258Dagher O, Mury P, Noly PE, Fortier A, Lettre G, Thorin E, Carrier M. Design of a Randomized Placebo-Controlled Trial to Evaluate the Anti-inflammatory and Senolytic Effects of Quercetin in Patients Undergoing Coronary Artery Bypass Graft Surgery. Front Cardiovasc Med. 2021 Oct 20;8:741542. doi: 10.3389/fcvm.2021.741542. eCollection 2021.
Individual participant dataSharing planned: No

Related trials for Coronary Artery Disease

Not yet recruitingObservational study
Assessment of Transnational Performance of the Universal Cardiac Surgical Risk Score Across International Sites
Heart Valve Diseases, Cardiac Surgical Procedures
Not yet recruiting
Sirolimus-Coated Versus Paclitaxel-Coated Balloon for Recurrent Coronary In-Stent Restenosis After Prior Paclitaxel-Coated Balloon Treatment (SPRIT)
Coronary In-stent Restenosis, Coronary Artery Disease
RecruitingObservational study
Norepinephrine in the Management of General Anesthesia-Induced Arterial Hypotension in Chronic Heart Failure Patients
Hypotension
Active, not recruitingObservational study
The CoPenHagen PREeClampsia and cardIOvascUlar diSease Study
Pre-Eclampsia, Atherosclerosis
RecruitingObservational study
Cardiovascular Risk Assessment For Kidney Transplantation - Utility of Computed Tomography Coronary Angiography in the Assessment of Patients Awaiting Kidney Transplantation
Cardiovascular Diseases, Kidney Transplant; Complications

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Michel Carrier, MD principal investigator

Montreal Heart Institute

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Quercetin in people with Coronary Artery Disease, run by Montreal Heart Institute at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 15 Apr 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Quercetin-associated Change in Surgery-associated Inflammation (time frame: Baseline, 1 day and 4 days post-surgery). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04907253, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2026.